News Releases

Sensus Healthcare to Participate in Panel Discussion at the Cantor Fitzgerald Dermatology & Aesthetics Summit

BOCA RATON, Fla., June 12, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare, will participate in a panel discussion, titled "New Treatments for Rare/Orphan Diseases and Oncologic Conditions," at the Cantor Fitzgerald Dermatology & Aesthetics Summit on Tuesday, June 19 at 2:00pm ET in New York.  The Summit is being held at the Westin Grand Central Hotel.

Mr. Sardano's participation will not be webcast, but a copy of the Company's corporate presentation is available in the Investors section of the Company's website at

About Sensus Healthcare
Sensus Healthcare, Inc., is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market. For more information, visit

LHA Investor Relations
Kim Sutton Golodetz

SOURCE Sensus Healthcare, Inc.

Products in Development - Evofem